Advances in the Diagnosis and Management of Age-Related Macular Degeneration: 3rd Edition

Dear Colleagues,

Age-related macular degeneration (AMD) is a major cause of legal blindness in developed nations. AMD is classified into two types: neovascular and non-neovascular (atrophic) AMD. Recent advances in imaging and therapeutic approaches have improved visual outcomes in eyes with neovascular AMD; that is, anti-vascular endothelial growth factor (VEGF) therapy has become the first-line treatment, supported by multimodal imaging with optical coherence tomography (OCT), fundus photography, fluorescein and indocyanine green angiography, OCT angiography, etc. Photodynamic therapy (PDT) is seldom used at this moment, especially in Western countries; despite this, PDT is still useful in the treatment of polypoidal choroidal vasculopathy and other pachychoroid diseases, which are predominant phenotypes in Asia. Future candidates of new treatment modalities include drug delivery for bioactive proteins, such as anti-VEGF agents, stem-cell-derived retinal pigment epithelial cell or photoreceptor transplant, gene therapy to produce soluble VEGF receptors, neurotrophic factors (e.g., pigment epithelium-derived factor), etc. New drugs have targeted even atrophic AMD, exemplified by complement inhibitors. In spite of these challenging approaches, this sight-threatening disease should be prevented via the use of prophylactic approaches, including antioxidant supplementation.

We previously launched the Special Issue “Advances in the Diagnosis and Management of Age-Related Macular Degeneration” Volume 1 and Volume 2 (https://www.mdpi.com/journal/jcm/special_issues/INK8O7U28B, https://www.mdpi.com/journal/jcm/special_issues/T1BG4AF421), in which various important novel findings and review articles were published and attracted significant attention. Because of the substantial need for and special interest in this field, we decided to launch “Advances in the Diagnosis and Management of Age-Related Macular Degeneration: 3rd Edition” as a sequel to the previous Special Issue.

This Special Issue will recruit original works or reviews regarding the recent status and advances in the diagnosis as well as management of neovascular and non-neovascular AMD.

Prof. Dr. Tsutomu Yasukawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.